can semaglutide cause fatty liver Pharmacotherapy for Non-alcoholic Disease Associated with Diabetes Mellitus Type 2 Therapeutic Effects of Glucagon-like Peptide-1

Scr, serum creatinine

Yes, research supports modest 1-2 kg weight loss, especially for overweight individuals

(2025 Definitive Guide) (2025) www.medicaldirectorco.com MedicalDirector Co

Written By: Pharmacally Medical News Desk AstraZenecas investigational oral GLP1 receptor agonist elecoglipron (AZD5004) is advancing toward Phase III development, supported by positive Phase IIb data in both type 2 diabetes and chronic weight management as outlined in the companys FY 2025 Clinical Trials Appendix

The National Institute for Health and Care Excellence (NICE) recommends specific GLP-1 receptor agonists in defined circumstances for type 2 diabetes when metformin and other treatments are insufficient, and for weight management through specialist services for people meeting specific criteria